Navigation Links
BioMarin Announces Third Quarter 2008 Financial Results
Date:10/28/2008

ths Ended Nine Months Ended

September 30, September 30,

2007 2008 2007 2008

Revenues:

Net product revenues $21,325 $67,812 $60,600 $185,895

Collaborative

agreement revenues 3,107 2,414 10,758 7,389

Royalty and license

revenues 574 2,420 5,369 3,933

Total revenues 25,006 72,646 76,727 197,217

Operating expenses:

Cost of sales 4,460 14,063 13,135 40,844

Research and

development 17,241 26,175 54,585 67,559

Selling, general and

administrative 19,521 28,964 53,075 77,836

Amortization of

acquired intangible

assets 1,093 1,093 3,278 3,278

Total operating

expenses 42,315 70,295 124,073 189,517

Income (loss) from

operations (17,309) 2,351 (47,346) 7,700

Equity in the income

(loss) of

BioMarin/Genzyme LLC 8,446 (572) 21,159 (1,692)

Interest income 7,948 3,407 18,549 13,157

Interest expense (4,109) (4,105) (10,163) (12,297)

Income (loss) before

income taxes (5,024) 1,081 (17,801) 6,868

Provision for income

taxes 192 252 572 543

Net income (loss) $(5,216) $829 $(18,373) $6,325

Net income (loss)

per share, basic $(0.05) $0.01 $(0.19) $0.06

Net income (loss)

per share, diluted $(0.05) $0.01 $(0.19) $0.06

Weighted average

common sh
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. BioMarin Corrects Information Included in Bloomberg Article
2. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
3. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
4. BioMarin to Present at the Citi Biotech Day
5. BioMarin Announces Roll-Out of National PKU Registry
6. BioMarin to Host Second Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, August 5 at 5:00 p.m. ET (23:00 CET)
7. BioMarin to Present at the Collins Stewart Growth Conference
8. SciQuest Announces Newest Life Sciences Customer; BioMarin Pharmaceutical Drives Spending Effectiveness with Automated, Intuitive Procurement
9. BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
10. BioMarin to Host Research and Development Day June 5th
11. BioMarin to Present at the Bank of America Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 2, 2015 /CNW/ - Shell today celebrated ... in the premium category with an exhibit the size ... that included interactive demonstrations for media and the public, ... Shell V-Power NiTRO+ Premium Gasoline provides the best total ... engine performance: engine wear, gunk and corrosion. ...
(Date:6/2/2015)... Tauriga Sciences, Inc. (OTCQB:  TAUG) ("Tauriga" or ... interests in the natural wellness sector and in ... announced that it has officially extinguished all further ... for a one-time cash payment of $230,000 USD.  ... entered into a Settlement Agreement (the "Settlement Agreement") ...
(Date:6/2/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/l5jcdk/genotyping_market ) has ... Technology, Application & by Products - Global Forecast to ... global genotyping market is expected to reach $17.0 Billion ... CAGR of 22.3% during the forecast period of 2015 ... to the availability of a range of products for ...
(Date:6/2/2015)... June 02, 2015 “Stem Cell Therapy to ... mainstream, and it is used often as an adjunct to ... practitioners are not yet aware or comfortable enough with the ... is most often reserved for the last resort cases - ... can barely lift a paw to get around. It is ...
Breaking Biology Technology:New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 2New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 3New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 4Tauriga Sciences, Inc. Extinguishes All Further Obligations to Typenex Co-Investment LLC with One-Time Cash Payment of $230,000 USD 2Tauriga Sciences, Inc. Extinguishes All Further Obligations to Typenex Co-Investment LLC with One-Time Cash Payment of $230,000 USD 3Tauriga Sciences, Inc. Extinguishes All Further Obligations to Typenex Co-Investment LLC with One-Time Cash Payment of $230,000 USD 4Genotyping Market Report 2015 by Technology, Application & by Products - Global Forecast to 2020 for the $17 Billion Market 2VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 2VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 3
... ChemoCentryx, Inc. today announced positive preclinical results for its ... the American Society of Nephrology. CCR2 inhibition in diabetic ... serum markers of renal function, and hyperglycemia.  These data ... Inhibition in Diabetic Mice Results in a Rapid and ...
... Nov. 10, 2011 Sequenom, Inc. (NASDAQ: SQNM ... today announced the Company,s participation at the Lazard Capital Markets ... York City November 15-16, 2011. Harry F. Hixson, ... Director and EVP of Research and Development, will present on ...
... The report " Lung Cancer Drugs ... http://www.marketsandmarkets.com/Market-Reports/lung-cancer-drugs-market-508.html ] " analyzes and studies the major ... Browse in-depth TOC on   ... 2020). Get Free 10% ...
Cached Biology Technology:ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology 2ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology 3Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference 2MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020 2MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020 3MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020 4
(Date:5/27/2015)... 27, 2015   Codonics (codonics.com), ... and image documentation solutions and Omnicell ... automation solutions, is pleased to announce their ... Safe Label System® (SLS), an award-winning FDA ... the Omnicell Anesthesia Workstation, helps prevent medication ...
(Date:5/22/2015)... -- According to a new market research ... Emotion, Forensic), by Software (Middleware, Databases), by Hardware (Cameras, Integrated ... Home) - Global Forecast to 2020", published by MarketsandMarkets, ... 2015 to $6.19 Billion by 2020, at a CAGR ... Tables and   43 Figures spread through 140 Pages ...
(Date:5/20/2015)... , May 20, 2015 NXT-ID, Inc. ... that its wholly owned subsidiary, 3D-ID LLC, a company ... Team Battelle for the biometrics technology portion of the ... Contract from the Department of the Army. ... products developed for government, law enforcement and security agencies. ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... 2009 - Collaboration in prostate cancer translational research in ... achieved in recent years but also to streamline current ... overlaps. This was amongst the goals of the two-day ... opened today in Amsterdam, The Netherlands. "It ...
... Outstanding International Horticulturist Award from the American Society for ... recognition of her longstanding and valuable contribution to international ... award on 25 July 2009 at the annual ASHS ... co-editor of the books Genetics and Genomics of Rosaceae ...
... -- Predation is one of the most fundamental and fascinating ... predators on Earth. However, their hunting pattern is difficult to ... a result, shark predatory behavior has remained much of a ... using geographic profiling -- a criminal investigation tool used to ...
Cached Biology News:Prostate Cancer Translational Research in Europe meeting: Search for biomarkers continues 2Prostate Cancer Translational Research in Europe meeting: Search for biomarkers continues 3Geographic profiling applied to track hunting patterns of white sharks in South Africa 2
Mouse monoclonal antibody to ST8SIA2 - ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2...
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse monoclonal antibody raised against a partial recombinant RAB11B. NCBI Entrez Gene ID = RAB11B...
...
Biology Products: